Drug resistant neoplasms (Record no. 6912)

MARC details
000 -LEADER
fixed length control field 04362nam a2200397 a 4500
001 - CONTROL NUMBER
control field EBC3019634
003 - CONTROL NUMBER IDENTIFIER
control field MiAaPQ
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cn|||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 090625s2009 nyua sb 001 0 eng d
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
Canceled/invalid LC control number 2009026399
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9781607412557 (hardcover)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 1607412551 (hardcover)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9781613244746 (e-book)
035 ## - SYSTEM CONTROL NUMBER
System control number (MiAaPQ)EBC3019634
035 ## - SYSTEM CONTROL NUMBER
System control number (Au-PeEL)EBL3019634
035 ## - SYSTEM CONTROL NUMBER
System control number (CaPaEBR)ebr10671199
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)738478182
040 ## - CATALOGING SOURCE
Original cataloging agency MiAaPQ
Transcribing agency MiAaPQ
Modifying agency MiAaPQ
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC271.C5
Item number D778 2009
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.99/4061
Edition number 22
245 00 - TITLE STATEMENT
Title Drug resistant neoplasms
Medium [electronic resource] /
Statement of responsibility, etc. Ethan G. Verrite, editor.
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. New York :
Name of publisher, distributor, etc. Nova Science Publishers,
Date of publication, distribution, etc. c2009.
300 ## - PHYSICAL DESCRIPTION
Extent xiv, 254 p. :
Other physical details ill.
490 1# - SERIES STATEMENT
Series statement Cancer etiology, diagnosis and treatments series
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Therapeutic implications of the intrinsic and acquired resistance of cancer stem/progenitor cells in inefficacy of current cancer treatments and disease relapse / Murielle Mimeault and Surinder K. Batra -- Role of O6-methyl guanine-DNA methyl transferase and the effect of O6-benzylguanine in cancer chemotherapy / Jun Murakami ... [et al.] -- The role of tumoural micro-environment and its vasculature on chemotherapy drug resistance: the potential for it's modulation to achieve therapeutic gain / A. Weickhardt and M. Michael -- Inherent and microenvironment-mediated mechanisms of drug resistance / Malathy P.V Shekhar -- Studies on the mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor gefitinib in NSCLC cell lines: evidence that ligand-induced endocytosis of EGFR via the early/late endocytic pathway is associated with gefitinib sensitivity of NSCLC cell line / Yukio Nishimura -- Mechanisms of resistance to EGF receptor-tyrosine kinase inhibitor in NSCLC cell lines: gefitinib sensitivity is closely correlated with ligand-induced endocytosis of phosphorylated EGF receptor / Yukio Nishimura, Kiyoko Yoshioka and Kazuyuki Itoh -- Targeting adverse features of hormone-resistant breast cancer / Stephen Hiscox ... [et al.] -- Systematic analysis of patterns of cross resistance between anticancer agents / Britta Stordal and Ross Davey -- Molecular structure and energy: clinical importance in drug resistant neoplasms / Viroj Wiwanitkit -- Treating drug resistant malignancy / Viroj Wiwanitkit -- Overcoming ovarian cancer drug resistance with phytochemicals and other compounds / Marion M. Chan and Dunne Fong -- New research communications on cancer drug resistance, assessment of cancer drug resistance with nuclear medicine images / Seigo Kinuya.
520 ## - SUMMARY, ETC.
Summary, etc. "One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Frequently, resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells. Studies on the mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and its implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field"--Publisher's description.
533 ## - REPRODUCTION NOTE
Type of reproduction Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug resistance in cancer cells.
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Verrite, Ethan G.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element ProQuest (Firm)
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer etiology, diagnosis, and treatments.
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://ebookcentral.proquest.com/lib/nird-ebooks/detail.action?docID=3019634">https://ebookcentral.proquest.com/lib/nird-ebooks/detail.action?docID=3019634</a>
Public note Click to View

No items available.

Installed and Supported by focuz infotech